Abbott's XIENCE V Cleared for Treatment of Coronary Artery Disease

 
February 10, 2009

Abbott Vascular's XIENCE V Everolimus-Eluting Coronary is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (up to 28 mm long) with reference vessel diameter of 2.5 to 4.09 mm.

More like this

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.

Related News

Zilver PTX Drug Eluting Stent Recalled Due to Catheter Separation Issue

April 30, 2013 — Cook Medical has initiated a global voluntary recall of its Zilver PTX Drug Eluting Peripheral...

With Resolute Stent, Interrupting DAPT After One Month Showed No Increased Risk

March 28, 2013 — Cardiologists at ACC.13 learned that patients with coronary artery disease who received a Resolute...

First Patient Treated in DIRECT II Study of Svelte DES With Bioresorbable Drug Carrier

March 20, 2013 — Svelte Medical Systems announced treatment of the first patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting...

View all

Related Articles

Promus Premier DES Receives European Approval

February 18, 2013 — Boston Scientific received CE mark approval for the Promus Premier everolimus-eluting platinum chromium coronary stent system, the company's next-generation durable polymer...

First U.S. Patient Treated with Cook Medical’s Zilver PTX Drug-Eluting Peripheral Stent

January 16, 2013 — Just weeks after the Food and Drug Administration (FDA) approved Cook Medical’s Zilver PTX drug-eluting peripheral stent, Riverside Methodist Hospital in Columbus,...

Abbott Initiates U.S. Trial for Fully Bioresorbable Stent

January 8, 2013 — Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States. The randomized controlled trial will enroll about 2,250 patients, the majority...

View all